<DOC>
	<DOCNO>NCT02252523</DOCNO>
	<brief_summary>This open , prospective pilot study pharmacological analysis . This study design assess efficacity safety dexmedetomidine-based sedation two subgroup neurocritically ill patient require mechanical ventilation 48 hour . Those risk intracranial hypertension require deep sedation require light moderate sedation early neurological evaluation . The main objective ass feasability dexmedetomidine infusion term efficacy safety ( especially cardiovascular tolerance ) brain-injured patient admit intensive care unit require sedation mechanical ventilation predictable duration great equal 48 hour . Secondary objective include study hemodynamic parameter evolution , dose-response relationship , blood ( +/- cerebrospinal fluid ) drug concentration , opioates co-hypnotic consumption .</brief_summary>
	<brief_title>Dexmedetomidine-based Sedation Neurocritical Care Patients</brief_title>
	<detailed_description>A write informed consent obtain patient next-of-kin , study enrollment accord inclusion exclusion criterias . All consecutive brain-injured patient ( traumatic brain injury , subarachnoid intracerebral hemorrhage , postoperative neurosurgical procedure ) admit neurocritical care unit , old 18 year require sedation analgesia mechanical ventilation longer 48 hour , eligible study . Depending absence presence lesion may increase intracranial pressure , patient include `` light moderate '' sedation subgroup ( MLS ) `` deep '' sedation subgroup ( DS ) . In MLS subgroup ( RASS 0/-3 ) , sedation analgesia drive propofol opiate . Once goals sedation achieve usual hypnotic , dexmedetomidine initiate dose 0.5 μg/kg/h , gradually increase decreased increment 0.1 μ g / kg / h hour maximum dose 1.4 μg/kg/h , depend target sedation achievement . Propofol discontinue study drug initiation . Dexmedetomidine infusion bemaintained least 48 hour , evaluation efficacy safety continuous period . After first 48 hour , absence neurological worsen require deep sedation sedation 's level achieve dexmedetomidine alone ( ie without requirement propofol continuous administration ) , maintain untill withdrawal mechanical ventilation . Otherwise , study drug discontinue propofol restart . In DS subgroup , `` deep '' sedation ( RASS -4/-5 ) achieve propofol infusion . If sedation level achieve maximum recommended propofol dose ( 5mg/kg/h ) , midazolam start reach target sedation level maximum dose 0.15mg/kg/h . Once goals sedation achieve dexmedetomidine infusion initiate dose 0.5 μg/kg/h gradually titrate increase 0.1 μg/kg/h every hour maximum patient-tolerated dose ( maximum dose 1.4 μg/kg/h ) . Conventional hypnotic dos adjust accord sedation target . In parallel dexmedetomidine titration , midazolam first propofol decrease . The study drug maintain maximum patient-tolerated dose total 48 hour efficacy safety assess continuously . After period , dexmedetomidine discontinue . According patient 's neurological evolution , either sedation objective remain identical ( RASS -4/-5 ) , sedation decrease . Conventional hypnotic use achieve objective . The expected result study confirm administration dexmedetomidine effective safe `` light moderate '' `` deep '' sedation brain-injured patient admit intensive care unit . In addition , feasibility study could provide legitimacy result conclusive , conduct prospective multicenter randomize control trial potential benefit dexmedetomidine neurocritical ill patient .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Braininjured patient ( traumatic brain injury , subarachnoid intracerebral hemorrhage , postoperative neurosurgical procedure ) Older 18 year Requiring sedation analgesia mechanical ventilation longer 48 hour Written inform consent obtain patient nextofkin , study enrollment Depending absence presence lesion may increase intracranial pressure , patient include `` light moderate '' sedation subgroup `` deep '' sedation subgroup Heart rate &lt; 45 bpm , Uncontrolled shock cardiac failure , Highgrade AV block , Acute ischemic neurological injury , Severe liver failure , Drug overdose prior enrollment trial experimental drug last 30 day , Need ongoing neuromuscular blockade except tracheal intubation , Pregnancy/lactation , Known allergic reaction dexmedetomidine , Uncontrolled diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Feasibility study</keyword>
</DOC>